 The CSIR then granted United Kingdom-based Phytopharm a license, and they collaborated with the pharmaceutical company Pfizer to isolate active ingredients from the extracts and look into synthesizing them for use as an appetite suppressant.Pfizer released the rights to the primary ingredient in 2002.Paul Hutson, associate professor in the University of Wisconsin–Madison School of Pharmacy, told the "Wisconsin State Journal", "For Pfizer to release something dealing with obesity suggests to me that they felt there was no merit to its oral use."